Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.044
- Book/Share 16.3757
- PB 1.579
- Debt/Equity 0.665
- CurrentRatio 1.2822
- ROIC 0.1065
- MktCap 146549112153.0
- FreeCF/Share 1.8252
- PFCF 14.1239
- PE 14.9202
- Debt/Assets 0.2957
- DivYield 0.0667
- ROE 0.1091
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Scotiabank | -- | Sector Outperform | -- | $30 | Nov. 13, 2025 |
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
Published: December 01, 2025 by: Investopedia
Sentiment: Neutral
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Read More
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Published: December 01, 2025 by: Market Watch
Sentiment: Negative
Memo also reportedly mentions vaccines for flu and pneumonia.
Read More
8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills
Published: November 28, 2025 by: Seeking Alpha
Sentiment: Positive
Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result in higher yields; eight of the top ten are already at ideal pricing levels.
Read More
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Read More
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
Read More
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
Published: November 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy.
Read More
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
Read More
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Pfizer CEO: AI will help with medicine's next big breakthrough
Published: November 13, 2025 by: Yahoo Finance
Sentiment: Positive
Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright. The company plans to enter the GLP-1 space by 2028 and aims to become a leader in the obesity market.
Read More
Pfizer Completes Acquisition of Metsera
Published: November 13, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. “This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth ther.
Read More
Metsera shareholders vote for $10 billion acquisition by Pfizer
Published: November 13, 2025 by: Reuters
Sentiment: Positive
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk.
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
Published: November 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).
Read More
5 Highest Yielding Dividend Stocks in the S&P 500
Published: November 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants.
Read More
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Published: November 10, 2025 by: Proactive Investors
Sentiment: Positive
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.
Read More
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Read More
Pfizer to buy Metsera in deal worth up to $10 billion
Published: November 10, 2025 by: CNBC Television
Sentiment: Positive
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Read More
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Published: November 10, 2025 by: CNBC Television
Sentiment: Positive
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical development and manufacturing.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.
Read More
Pfizer: The Storm Has Passed -- Tailwinds Ahead
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. remains a Strong Buy with a $33 price target, implying 33% upside over 12-18 months, driven by undervaluation and sector tailwinds. Despite Fiscal Q3 2025 revenue and EPS declines, PFE's future outlook is improving, with new product launches and acquisitions expected to offset losses of exclusivity. PFE's robust dividend yield near 7%, shareholder-friendly capital allocation, and potential Metsera acquisition offer downside protection and growth catalysts.
Read More
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Read More
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Published: November 06, 2025 by: Benzinga
Sentiment: Neutral
The Delaware Chancery Court denied Pfizer Inc.'s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk A/S (NYSE:NVO).
Read More
No Brainer Dividend Stocks To Buy Now
Published: November 06, 2025 by: 24/7 Wall Street
Sentiment: Positive
You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating cash income from their portfolio, but if you handle the income well, you can generate a higher total return through dividend reinvestment while boosting the long-term capital appreciation potential.
Read More
Pfizer says it removed some conditions from its Metsera bid
Published: November 05, 2025 by: Reuters
Sentiment: Neutral
Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.
Read More
Pfizer: Market Still Pricing It At Crisis Valuations
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer multiple growth pathways, even if the Metsera acquisition turns out to be unsuccessful. The GLP-1 market's increasing competition and pricing pressures may weigh on PFE sentiment, but strong free cash flows and appealing dividend yield support a bullish view.
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Published: November 05, 2025 by: CNBC
Sentiment: Positive
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Read More
Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. ( PFE ) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO David Denton - Executive VP & CFO Aamir Malik Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Courtney …
Read More
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
Published: November 04, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000